Literature DB >> 33628759

Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements.

Ivana Mikolasevic1,2,3, Goran Hauser1,3,4, Maja Mijic2, Viktor Domislovic5, Delfa Radic-Kristo6,7, Zeljko Krznaric5,7, Melanija Razov-Radas8, Tajana Pavic7,9, Marija Matasin7, Tajana Filipec Kanizaj2,7.   

Abstract

Aim: The primary objective of this study was to evaluate the prevalence of increased controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) as surrogate markers of liver steatosis and fibrosis in liver transplant recipient (LTR). Secondary objectives were to determine the predictors of increased CAP and LSM in population of LTR.
Methods: In this prospective, cross-sectional study, we have evaluated 175 LTRs' mean age as 61 (53-65) with a functioning graft for more than one year who came for regular outpatient examinations to the Department of Gastroenterology, University Hospital (UH) Merkur, Zagreb, Croatia.
Results: Of 175 analyzed LTRs, 34.28% had obesity, 64.00% had hypertension, 38.28% had diabetes, and 58.85% had hyperlipidemia. The prevalence of liver steatosis was 68.57%, while the prevalence of severe liver steatosis was 46.85%. On multivariate analysis, independent factors associated with liver steatosis were male gender, total cholesterol as positive predictor, and HDL as negative predictor, and independent factors positively associated with severe liver steatosis were higher body mass index (BMI) and higher triglyceride levels. The prevalence of moderate liver fibrosis was 54.85%, while the prevalence of advanced liver fibrosis was 24%. On multivariate analysis, independent factors positively associated with moderate fibrosis were gamma-glutamyl transferase (GGT) and CAP, while the independent factor positively associated with advanced fibrosis was GGT.
Conclusion: Our study showed high prevalence of increased CAP and LSM measurements as surrogate markers of liver steatosis and fibrosis. Metabolic syndrome components were highly present and were associated with CAP and LSM values as well as in the pretransplant setting. Due to high prevalence of metabolic comorbidities and nonalcoholic fatty liver disease in LTRs and the lack of the abnormal liver test in a significant number of these patients, TE with CAP may be a reasonable initial assessment for LTRs with one or more components of the metabolic syndrome.
Copyright © 2021 Ivana Mikolasevic et al.

Entities:  

Year:  2021        PMID: 33628759      PMCID: PMC7889377          DOI: 10.1155/2021/6657047

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  30 in total

1.  Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography.

Authors:  Ivana Mikolasevic; Sanjin Racki; Ivan Bubic; Ita Jelic; Davor Stimac; Lidija Orlic
Journal:  Kidney Blood Press Res       Date:  2013-09-12       Impact factor: 2.687

Review 2.  A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient.

Authors:  Adam C Winters; Rasham Mittal; Thomas D Schiano
Journal:  Clin Transplant       Date:  2019-09-08       Impact factor: 2.863

3.  Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.

Authors:  Ivana Mikolasevic; Sandra Milic; Lidija Orlic; Davor Stimac; Neven Franjic; Giovanni Targher
Journal:  J Diabetes Complications       Date:  2016-05-20       Impact factor: 2.852

4.  De novo nonalcoholic fatty liver disease after liver transplantation.

Authors:  Suk Seo; Kalyani Maganti; Manjit Khehra; Rajendra Ramsamooj; Alexander Tsodikov; Christopher Bowlus; John McVicar; Mark Zern; Natalie Torok
Journal:  Liver Transpl       Date:  2007-06       Impact factor: 5.799

Review 5.  Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation.

Authors:  Ivana Mikolasevic; Lidija Orlic; Irena Hrstic; Sandra Milic
Journal:  Hepatol Res       Date:  2016-02-04       Impact factor: 4.288

6.  De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients.

Authors:  Stefano Gitto; Nicola de Maria; Fabrizio di Benedetto; Giuseppe Tarantino; Valentina Serra; Lorenzo Maroni; Matteo Cescon; Antonio D Pinna; Filippo Schepis; Pietro Andreone; Erica Villa
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-07       Impact factor: 2.566

7.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

Review 8.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography.

Authors:  I Mikolasevic; S Racki; V Lukenda; S Milic; M Pavletic-Persic; L Orlic
Journal:  Transplant Proc       Date:  2014-05-15       Impact factor: 1.066

10.  Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation.

Authors:  Praveena Narayanan; Kristin Mara; Manhal Izzy; Ross Dierkhising; Julie Heimbach; Alina M Allen; Kymberly D Watt
Journal:  Transplantation       Date:  2019-01       Impact factor: 4.939

View more
  1 in total

1.  Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study.

Authors:  Alshaima Alhinai; Afsheen Qayyum-Khan; Xun Zhang; Patrick Samaha; Peter Metrakos; Marc Deschenes; Philip Wong; Peter Ghali; Tian-Yan Chen; Giada Sebastiani
Journal:  World J Hepatol       Date:  2021-12-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.